Genetron Holdings Limited (GTH)

Market Cap	92.41M
Revenue (ttm)	81.71M
Net Income (ttm)	-104.66M
Shares Out	90.60M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Open	1.01
Previous Close	1.02
Day's Range	1.01 - 1.05
52-Week Range	0.73 - 3.01
Beta	0.50
Analysts	Buy
Price Target	3.00 (+194.12%)
Earnings Date	Mar 29, 2023

About GTH

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 1,154
• Stock Exchange: NASDAQ
• Ticker Symbol: GTH

Financial Performance

In 2021, GTH's revenue was 531.95 million, an increase of 25.32% compared to the previous year's 424.49 million. Losses were -496.24 million, -83.83% less than in 2020.

Financial numbers in CNY

Analyst Forecast

According to 5 analysts, the average rating for GTH stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 194.12% from the latest price.

Price Target

$3.0

(194.12% upside)

Analyst Consensus: Buy